|1.94|| +0.02 / +1.04%|
Synthetic Biologics, Inc. is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The company developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of C. diff infection, an oral treatment to reduce the impact of methane producing organisms on conditions such as constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. Synthetic Biologics was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
|Jeffrey Lucero Riley||President, Chief Executive Officer & Director|
|John James Monahan||Executive Vice President-Research & Development|
|Joseph Sliman||Senior VP-Clinical & Regulatory Affairs|
|Lara M. Guzman||Senior Director-Project Operations|
|Michael Kaleko||Senior Vice President-Research & Development|